Regina Hodits

Managing Partner at Wellington Partners

Speaker

Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma Therapeutics, ONWARD, Sidekick, SNIPR Biome and STipe Therapeutics. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), represented Wellington Partners of the Board of Themis (acquired by MSD), and served as the Spokesperson for the Board of the German PE and VC Association (BVK). Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences.

Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC), F-star (NASDAQ,: FSTX) and Jenavalve, and served on the Boards of U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), and Novamed (acquired by SciClone NASDAQ SCLN). Before, Regina worked for Apax Partners and McKinsey.

Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry, and was as post-doctoral researcher at the MRC, Cambridge UK.